Matinas 10-Q: Going-Concern Doubt With $1.9M Cash as GH Power Merger and Azurity Sale Pending
MTNB is trading near its 52-week low of $0.807 (15% above the low).
Summary
Matinas reported $1,936K of cash at September 30, 2026 and said it cannot fund operations for twelve months, leaving the pending GH Power merger and Azurity asset sale as its survival path.
Key Events · Earnings and Guidance · MTNB
-
Going-Concern Doubt Disclosed
Cash and cash equivalents of $1,936K plus $50K restricted cash at September 30, 2026 are not sufficient to fund planned operations for at least twelve months from the filing date; accumulated deficit stands at $222,920K.
-
GH Power Merger Terms
Under the July 10, 2026 Business Combination Agreement, each Matinas share converts into 0.1 of a Pubco common share; current Matinas holders are expected to own about 9% of Pubco versus 91% for GH Power holders, based on a $24,725K Matinas valuation and $250,000K GH Power valuation.
-
Azurity Asset Sale Consideration
Azurity will buy Nanotechnologies (owner of MAT2203) for up to $21,500K cash — $4,000K at closing, subject to debt adjustment, plus up to $17,500K on milestones — and a mid-single-digit royalty; former Series A holders receive 7.5% of proceeds.
-
NYSE American Equity Deficiency
Notices dated April 2, 2026 and June 24, 2026 flagged noncompliance with stockholders' equity standards; NYSE American accepted the company's plan and granted a plan period through October 2, 2027. Continued listing is a closing condition for the merger.
Analysis · MTNB · Life Sciences
Substantial doubt about going concern now hangs over Matinas: at September 30, 2026 the company held $1,936K of cash and $50K of restricted cash, and management states plainly that this is not enough to fund operations for at least twelve months. Two deals signed July 10, 2026 offer the only paths out. The first is the GH Power business combination, under which existing Matinas holders would own roughly 9% of the combined company against GH Power holders' 91%. The second is the Azurity sale of Nanotechnologies for up to $21,500K — $4,000K at closing plus up to $17,500K in milestones. Should either fail, the board says it may pursue wind-down or liquidation, in which case stockholders could receive little or nothing. Layered on top is a NYSE American stockholders' equity deficiency, with a plan period running to October 2, 2027, and a listing condition attached to the merger itself.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTNB was trading at $0.93 on NYSE in the Life Sciences sector, with a market capitalization of approximately $908K. The 52-week trading range was $0.81 to $18.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.